A 58-year-old transgender woman is seen in clinic for a follow-up visit. She was diagnosed with HIV in the mid-1990's and has received multiple antiretroviral regimens, including several older HIV protease inhibitors. She experienced two prior episodes of virologic failure while taking older, less effective antiretroviral regimens. Prior HIV genotypic drug-resistance assays showed the reverse transcriptase mutations M41L, K103N, M184V, G190A, L210W, and the protease mutation D30N (not a darunavir-associated mutation). The tentative plan is to simplify the antiretroviral regimen and witha regimen of boosted darunavir, dolutegravir, and doravirine.